艾昆玮-印度医药市场季度洞察——2024年第一季度（英）-2024-13页
VIP专享
IQVIA Template (V2.1.0)
1
Disclaimer
IQVIA is not an “authorised person” for the purposes of the Financial Services and Markets Act 2000 (“FSMA”) and does not provide
investment advice or carry on any other regulated activity under Part II of the FSMA 2000 (Regulated Activities) Order 2001
The forecasts, projections, and related information contained herein are made and provided subject to the assumptions, methodologies,
caveats, and variables described in this report and are based on third party sources and data reasonably believed to be reliable. No
warranty is made as to the completeness or accuracy of such third party sources or data
This report, in part or in whole, is not intended to constitute investment advice, and is not a recommendation to purchase or not purchase,
an endorsement of, or an opinion as to the value of, any security or any investment instrument of any entity
As with any attempt to estimate future events, the forecasts, projections, conclusions, and other information included herein are subject to
certain risks and uncertainties, and are not to be considered guarantees of any particular outcome
This report shall not be published, nor shall any public references to IQVIA be made regarding these services or this report, without IQVIA’
prior written approval. When so provided, this report and the information herein must always be provided and used in its entirety, including
this complete Disclaimer page
This report is subject to the IQVIA General Terms and Conditions.
IQVIA Template (V2.1.0)
2
Market reflected growth of 6% in Q1 2024
10% 15% 10% 8% 9% 6%
•Overall IPM market size: ₹216092 Cr. (MAT Mar); ₹ 53,337 Cr (Q1 Mar 2024)
• Growth in Sales Value Previous Period Growth (‘PPG’): 8% (MAT); 6% (Q1 2024)
•Chronic TAs grew at 10% PPG whereas Acute TAs reflected single digit growth of 3%
PPG in Q1 2024
•Amongst Chronic TAs, Cardiac registered robust growth of 11% (PPG) and also led in
terms of absolute incremental value, followed by Neuro/CNS 8% (PPG), AntiDiabetic 7%
(PPG) and Chronic Respiratory 6% (PPG)
•Antineoplast, Pain, Uro also registered double digit growth
•Anti-infectives reflected degrowth of -2% (PPG). Gastro grew at 5% (PPG) and VMN
grew at 7% (PPG)
•Respiratory Acute degrew at -9% (PPG)
•Pain Acute and Derma grew in single digits.
•Relative performance: Indian Pharma Cos grew at 6% (PPG) compared to MNCs which
grew at 5% (PPG) for Q1 2024
•Sun, Cipla, Mankind, Intas reflected good growth among Top Indian Pharma Co’s while
Abbott, Sanofi, Janssen, Astrazeneca reflected good growths among Top MNC Pharma Co’s
•Number of new launches have decreased by -54% in 2024 as compared to 2023
MAT Progress, Val ₹ ‘000 Cr.
QTR Progress, Val ₹ ’000 Cr.
2020 2021 2022 2023 2024
150 157 186 201 216
+10%
+8%
Q4’22 Q1’23
51 50
Q2’ 23 Q3’ 23 Q4’ 23 Q1’ 24
52 56 55 53
MAT Mar 2024 vs. MAT Mar 2023 as well as Qtr. Jan-Mar 2024 vs. Qtr. Jan-Mar 2023 growth
Source: IQVIA TSA Mar 2024
摘要：
展开>>
收起<<
IQVIATemplate(V3.0.0)©2024.Allrightsreserved.IQVIA®isaregisteredtrademarkofIQVIAInc.intheUnitedStates,theEuropeanUnion,andvariousothercountries.IndianPharmaceuticalMarketQuarterlyInsights–Q12024(Jan-Mar)ReportReleaseDate:May2024Dataset:TSAMarch2024IQVIATemplate(V2.1.0)1DisclaimerIQVIAisnotan“authori...
相关推荐
-
电子书-原则：应对变化中的世界秩序-506页免费
2024-03-10 193 -
电子书--长期的力量：如何构建可持续的价值投资盈利体系 (梁宇峰）免费
2024-04-10 201 -
电子书：底层逻辑 刘润免费
2024-05-07 112 -
电子书-《知识炼金术（个人版）》免费
2024-05-15 152 -
电子书-《美国家庭财富百年史（1900~2013）》免费
2024-05-15 587 -
电子书-《波士顿咨询工作法：精准发现问题》免费
2024-05-15 144 -
电子书-《财富引路人：成功基金经理的经济学解释及投资备忘录》-289页免费
2024-05-16 205 -
电子书-《自品牌：社交媒体时代如何打造个人品牌》-215页免费
2024-05-16 534 -
【恒生电子】2024金融科技趋势研究报告免费
2024-05-20 131 -
方正证券-电子行业专题报告--中国科技企业新估值体系的探讨-240613-总144页VIP专享
2024-06-13 241
作者：村上
分类：按申万行业
价格：免费
属性：13 页
大小：324.88KB
格式：PDF
时间：2024-09-03
